Abstracts Reporting EarlyCDTâ„¢-Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection of Solid Tumor Lung Cancers
DENVER, May 12, 2011 /PRNewswire/ -- Oncimmune ® LLC , maker of EarlyCDT™-Lung , a simple blood test that aids physicians in the risk assessment and early detection of lung cancer , today announced that four poster presentations during the American Thoracic Society's (ATS) International Conference May 13 - 18 in Denver will collectively highlight the diagnostic and economic benefits of EarlyCDT-Lung . Oncimmune's EarlyCDT-Lung  test uses a panel of tumor antigens to detect the presence of immuno-biomarkers produced in the form of autoantibodies by the patient's immune system. Elevation of any one of the panel of immuno-biomarkers (autoantibodies) above a predetermined cut-off value suggests that a tumor might be present. These studies follow data presented at the American College of Chest Physicians in fourth quarter of last year.
The studies presented at the ATS meeting validate that EarlyCDT-Lung  detects all types of lung cancers at all stages, including early stage disease. Previous studies have shown that immuno-biomarkers can be detected up to five years before tumors can be seen in routine diagnostic imaging procedures such as CT.
Abstracts reporting EarlyCDT-Lung's diagnostic and economic benefits of immuno-biomarkers in early detection of solid tumor lung cancers during the ATS meeting include:
- Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT), Abstract: 21114, May 16, Poster viewing: 10:45 a.m. - 12:30 p.m.